Fianlimab

• A Study to Learn about the Long-Term Health of Adult Participants from a Previous Study of a New Melanoma Treatment Pending
  2024-517729-20-00 Phase II 1 country Regeneron Pharmaceuticals Inc.
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting
  2022-502825-17-00 Phase II 8 countries Regeneron Pharmaceuticals Inc.
• Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting
  2024-519208-29-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
• Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting
  2024-513375-40-00 Phase II 1 country Grupo Espanol Multidisciplinar De Melanoma
• LAG3 PET; ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with… Recruiting
  2024-516795-15-00 Phase II 1 country Universitair Medisch Centrum Groningen
• A study to learn if a combination of Fianlimab and Cemiplimab versus Cemiplimab alone is more effective for adult participants with Advanced… Ended
  2022-501483-18-00 Phase II/III 4 countries Regeneron Pharmaceuticals Inc.
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com… Ended
  2022-501576-25-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended
  2023-505772-30-00 Phase III 12 countries Regeneron Pharmaceuticals Inc.

Showing 1–8 of 8 trials